NEW YORK (GenomeWeb) – Molecular diagnostics developer DiaCarta announced today that its DiaCarta Clinical Services Laboratory has successfully passed the State of California survey under the Clinical Laboratory Improvement Amendments of 1988.

The lab now has permission to begin offering patient and clinical testing services for its QClamp-based molecular diagnostic. QClamp screens for tumor oncogenic driver and resistance mutations in tumor DNA derived from cancer patients.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.